{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:48Z","timestamp":1787070888685,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Pazopanib is an oral multitargeting tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs), approved as the first-line treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) at a fixed dose of 800 mg daily taken fasted. Potential drug\u2013meal interactions and adverse events (AEs) may lack recognition and the related data in literature. We report one case of stomatitis\/oral mucositis associated with pazopanib administrated with an oral nutritional supplement enriched with omega-3 fatty acids. The 50-year-old patient with mRCC started pazopanib treatment at standard doses of 800 mg daily as first-line therapy for mRCC, and after a few days, he developed stomatitis. Co-administration of pazopanib with high-fat meals could increase the solubility of highly lipophilic pazopanib, increasing its plasma pazopanib area under the curve (AUC), and maximum concentration (Cmax) above optimal therapeutic level can consequently lead to increased frequency\/grade of AEs.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_533_22","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:12:07Z","timestamp":1686618727000},"page":"474-476","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Co-administration of pazopanib and enteral nutrition with omega-3 fatty acids as a safety issue in a patient treated for metastatic clear cell renal cancer: A case report"],"prefix":"10.4103","volume":"19","author":[{"given":"Josipa","family":"Jovi\u0107 Zlatovi\u0107","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, General Hospital of \u0160ibenik-Knin County, \u0160ibenik, Croatia, Balkans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Omr\u010den","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, University Hospital Split, Split, Croatia, Balkans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Marijanovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina, Balkans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Kraljevi\u0107","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina, Balkans"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma:Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"R5-20241021","first-page":"203","article-title":"Administraci\u00f3n de citost\u00e1ticos v\u00eda oral:interacciones f\u00e1rmaco-alimento [Oral chemotherapy:food-drug interactions","volume":"39","author":"Santana Mart\u00ednez","year":"2015","journal-title":"Farm Hosp"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cpt.1515","article-title":"The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety and preference (DIET Study)","volume":"106","author":"Lubberman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/clpt.2010.199","article-title":"Aphase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors","volume":"88","author":"Heath","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"(Suppl 7)","key":"R9-20241021","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/jco.2011.29.7_suppl.345","article-title":"Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma","volume":"29","author":"Lin","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_533_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:18Z","timestamp":1787067498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_533_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_533_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-03-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}